title: Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.
abstract: BACKGROUND
  Vaccination is very important for the control and prevention of influenza, yet no vaccine is perfectly safe. Little is known, however, about influenza vaccination-associated serious adverse events following immunization (AEFI). This study aimed to identify background information on influenza vaccination-related serious AEFI in Korea.
  
  
  METHODS
  Retrospective review of data from Korea National Vaccine Injury Compensation Program from 2003 to 2010.
  
  
  RESULTS
  Distribution of approximately 75 million doses of influenza vaccine by end of 2010 gave rise to 42 potentially serious AEFI. In all, nine Guillain-Barré syndrome, eighteen other neurologic events, eight local events, and seven miscellaneous events were included. 62% of these events were identified to have unlike causal association with the vaccine. The reporting rate of serious AEFI ranged from 0.006 to 0.07 cases per 100,000 distributed doses of the vaccine.
  
  
  CONCLUSIONS
  GBS was the most common influenza vaccination-related serious AEFI. Enhancing post-vaccination GBS surveillance may increase public confidence in future routine and pandemic influenza vaccination.
authors.affiliation: Division of Vaccine Preventable Disease Control and National Immunization Program, Korea Centers for Disease Control and Prevention, Seoul, Republic of Korea. choeyj@yahoo.com
authors.forename: Young June
authors.initials: YJ
authors.lastname: Choe
authors.forename: Heeyeon
authors.initials: H
authors.lastname: Cho
authors.forename: Sung Nam
authors.initials: SN
authors.lastname: Kim
authors.forename: Geun-Ryang
authors.initials: GR
authors.lastname: Bae
authors.forename: Jong-Koo
authors.initials: JK
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D005260:Female; D020275:Guillain-Barre Syndrome / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D056910:Republic of Korea; D012189:Retrospective Studies; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines; D015164:Vaccines, Inactivated